you are here:

Lasa Supergenerics Ltd.

BSE: 540702 | NSE: LASA |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE670X01014 | SECTOR: Miscellaneous

BSE Live

Jun 22, 16:00
84.25 1.15 (1.38%)
Volume
AVERAGE VOLUME
5-Day
239,016
10-Day
186,897
30-Day
143,540
132,243
  • Prev. Close

    83.10

  • Open Price

    82.00

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

NSE Live

Jun 22, 15:57
84.60 1.45 (1.74%)
Volume
AVERAGE VOLUME
5-Day
676,857
10-Day
741,908
30-Day
503,598
499,165
  • Prev. Close

    83.15

  • Open Price

    83.50

  • Bid Price (Qty.)

    84.60 (1440)

  • Offer Price (Qty.)

    0.00 (0)

ANNOUNCEMENTS ON Lasa Supergener

  • Jun 14, 2021 14:41 Source: BSE

    Lasa Supergenerics - Disclosure Of Voting Results

    The resolution as set out in the notice of the said meeting was duly approved by the Equity Shareholders, with requisite majority. Voting Results Attached.

  • Jun 14, 2021 14:41 Source: BSE

    Lasa Supergenerics - Disclosure Of Voting Results

    The resolution as set out in the notice of the said meeting was duly approved by the Equity Shareholders, with requisite majority. Voting Results Attached.

  • Jun 13, 2021 11:08 Source: BSE

    Lasa Supergenerics - Proceedings Of The Hon'Ble NCLT / Court Convened Meeting (CCM) Of Equity Shareholders

    Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations 2015, as amended, we are submitting herewith the summary of proceedings of the Court Convened Meeting of the Company held on Saturday, June 12, 2021 at 10:30 A.M and commenced at 11:00 am Indian Standard Time ('IST') due to want of quorum, which then concluded at 11:45 am. (Including time allowed for e-voting at the CCM) through Video Conferencing/ Other Audio Visual Means ('VC/OAVM').

  • Jun 09, 2021 11:25 Source: NSE

    Lasa Supergenerics Limited

    Lasa Supergenerics Limited has informed the Exchange regarding a press release dated Jun 09, 2021, titled "Attached is the copy of Press Release titled LASA launches new product Oxyclozanide Creating new Capacity as a brown field expansion issued by the company.".

  • Jun 09, 2021 11:09 Source: BSE

    Lasa Supergenerics - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Attached is the copy of Press Release titled 'LASA launches new product - Oxyclozanide Creating new Capacity as a brown field expansion' issued by the company.

  • Jun 01, 2021 20:29 Source: BSE

    Lasa Supergenerics - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Attached is the copy of Press Release titled 'LASA SUPERGENERICS ANNOUNCES ROBUST PAT AT 22.80CRS, UP 521% YOY, with Recommendation of Dividend' issued by the company

  • Jun 01, 2021 13:31 Source: BSE

    Lasa Supergenerics - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that an earnings call will be held on Friday, June 04, 2021 at 02:00 p.m. IST for discussing the Audited financial results of the Company for the quarter and financial year ended March 31, 2021.

  • May 31, 2021 14:12 Source: BSE

    Lasa Supergenerics - Board recommends Final Dividend

    Lasa Supergenerics Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 31, 2021, inter alia, has recommendationof the final Dividend of Rs. 0.25 (2.5%) per equity share for the financial year ended March 31, 2021, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.

  • May 31, 2021 13:54 Source: BSE

    Lasa Supergenerics - Results- Financial Year Ended March 31, 2021

    Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 11:00 am and concluded at 01:30 p.m. inter- alia have considered and approved the following: 1. The Audited Financial Results of the Company for the Quarter and financial Year ended March 31, 2021. 2. Recommendation of the final Dividend of Rs 0.25 (2.5%) per equity share for the financial year ended March 31, 2021, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. A copy of the statement of audited Financial Results, Cash Flow statement along with Audited Report submitted by the Statutory Auditors of the Company is attached herewith.

  • May 31, 2021 13:47 Source: BSE

    Lasa Supergenerics - Outcome Of Board Meeting Held Today I.E. May 31, 2021

    Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 11:00 am and concluded at 01:30 p.m. inter- alia have considered and approved the following: 1. The Audited Financial Results of the Company for the Quarter and financial Year ended March 31, 2021. 2. Recommendation of the final Dividend of Rs 0.25 (2.5%) per equity share for the financial year ended March 31, 2021, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.

CORPORATE ANNOUNCEMENTS

BOARD MEETING

Meeting Date : May 31, 2021
Remark : Audited Results